Newscasting from EULAR 2024: Approximately Half of Patients Demonstrated Poor Health Literacy Prior to Biosimilar Switch
A real-world study showed patients with inflammatory bowel disease (IBD) or chronic inflammatory rheumatic disease treated with reference adalimumab who were switched to the biosimilar CT-P17 generally believed the switch was a treatment necessity. Higher satisfaction rates were observed among those who were convinced of the necessity compared with those with greater concerns about treatment.
However, health literacy levels were categorized as either problematic or insufficient in 51.3% of patients with longer disease duration and long-standing biologic use, according to data presented at the 2024 European Congress of Rheumatology (EULAR).
Source: MDMag
To view the third party content, kindly click on the link below or read more. You will then leave this site and enter a third party site.
